AMBER TOWE: Open Payments
NPI 1548729106 · SIKESTON, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,799 in 206 payments from 13 companies in 2025. Trend: 2023 $2,916 · 2024 $2,084 · 2025 $3,799
Food & beverage: $3,798Education: $1
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 52 | $813 |
| Teva Pharmaceuticals USA, Inc. | 30 | $803 |
| Vanda Pharmaceuticals Inc. | 30 | $503 |
| ABBVIE INC. | 29 | $460 |
| Alkermes, Inc. | 23 | $411 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $319 |
| Supernus Pharmaceuticals, Inc. | 14 | $197 |
| Otsuka America Pharmaceutical, Inc. | 5 | $93 |
| Lundbeck LLC | 4 | $93 |
| Janssen Pharmaceuticals, Inc | 2 | $57 |
Products named: INGREZZA, UZEDY, FANAPT, VRAYLAR, ARISTADA, CAPLYTA, AUSTEDO XR, Qelbree.
Industry payments across MO — which companies pay providers there.
